The U.S. biotech company was the last of three suitors standing in an auction for Horizon. A deal would likely be valued at well over $20 billion and mark the largest healthcare merger of the year.
The U.S. biotech company was the last of three suitors standing in an auction for Horizon. A deal would likely be valued at well over $20 billion and mark the largest healthcare merger of the year.